# Dexcom Moat

Status: published. Policy: company-analysis-1.

Dexcom has a narrow moat from commercialized CGM know-how, regulatory achievements and established reimbursement access, supported by a growing active customer base. These advantages require continued innovation and reliable manufacturing. Pricing discretion is constrained by payors and rebates; strong realized pricing power and durable customer lock-in are not established. Manufacturing deficiencies, inventory charges and future Medicare bidding create material erosion risks despite demonstrated growth and improved operating results.

## intangible_assets

Commercialized CGM technology, accumulated technical know-how, regulatory achievements and established formulary access create a current advantage in reaching and serving customers. Product launches, FDA clearance and approximately 3.5 million active customers support commercialization beyond management's statements of intent.

Durability: Recreating regulated products and commercial-scale manufacturing requires technical expertise, capital and time. Continued product development and reimbursement access support a narrow advantage, but the passages do not establish a lasting technological lead over competitors. The Abbott patent agreement reduces specified litigation exposure through a covenant ending December 20, 2034, while its reciprocal, non-exclusive licenses limit patent exclusivity.

Risks: The FDA warning letter and historical supply disruptions demonstrate execution weaknesses. Rising inventory reserves impose actual costs. Payor bargaining, rebates and Medicare bidding constrain monetization. Broader CGM coverage also benefits the category and is not necessarily exclusive to Dexcom.

Invalidation: The thesis would fail if persistent quality deficiencies caused material product restrictions or sustained supply losses, or if loss of formulary access and technological differentiation produced sustained declines in active customers and sales. Sustained reimbursement reductions that Dexcom could not offset through product value or production efficiencies would also undermine the advantage's economic value.

Competitors: Abbott
- [https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231.htm](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231.htm) · 2026-02-12
- [https://www.sec.gov/Archives/edgar/data/1093557/000109355726000143/dxcm-20260630.htm](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000143/dxcm-20260630.htm) · 2026-07-30
- [https://www.sec.gov/Archives/edgar/data/1093557/000109355726000061/dxcm-20260415.htm](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000061/dxcm-20260415.htm) · 2026-04-15
- [https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231.htm](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231.htm) · 2025-02-18
- [https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm-20231231.htm](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm-20231231.htm) · 2024-02-08
- [https://www.sec.gov/Archives/edgar/data/1093557/000109355726000073/dxcm-20260331.htm](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000073/dxcm-20260331.htm) · 2026-04-30

[JSON](https://beanvest.com/stock/dxcm/moat.json)